Kentucky Retirement Systems lowered its stake in IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 0.9% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 13,730 shares of the medical research company’s stock after selling 130 shares during the period. Kentucky Retirement Systems’ holdings in IQVIA were worth $2,903,000 as of its most recent filing with the SEC.
Other institutional investors also recently modified their holdings of the company. Rise Advisors LLC bought a new position in shares of IQVIA in the first quarter valued at $31,000. Versant Capital Management Inc increased its holdings in shares of IQVIA by 733.3% in the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after buying an additional 110 shares in the last quarter. Riverview Trust Co acquired a new stake in IQVIA during the 1st quarter valued at $32,000. Opal Wealth Advisors LLC acquired a new stake in IQVIA during the 2nd quarter valued at $27,000. Finally, International Assets Investment Management LLC acquired a new stake in IQVIA during the 2nd quarter valued at $32,000. Institutional investors own 89.62% of the company’s stock.
IQVIA Trading Up 0.8 %
Shares of NYSE:IQV opened at $244.62 on Friday. The stock has a market capitalization of $44.57 billion, a PE ratio of 33.42, a P/E/G ratio of 2.24 and a beta of 1.49. IQVIA Holdings Inc. has a 1 year low of $167.42 and a 1 year high of $261.73. The firm has a fifty day moving average price of $240.24 and a 200 day moving average price of $234.25. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 1.80.
Insider Buying and Selling at IQVIA
In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the sale, the insider now directly owns 19,536 shares in the company, valued at $4,812,302.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 1.60% of the company’s stock.
Wall Street Analyst Weigh In
Several analysts have issued reports on the stock. Morgan Stanley boosted their target price on shares of IQVIA from $270.00 to $280.00 and gave the company an “overweight” rating in a research note on Tuesday, July 23rd. Jefferies Financial Group downgraded shares of IQVIA from a “buy” rating to a “hold” rating and cut their target price for the company from $266.00 to $242.00 in a research note on Wednesday, July 24th. StockNews.com raised shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Thursday, September 5th. Argus raised shares of IQVIA to a “strong-buy” rating in a research note on Wednesday, July 31st. Finally, UBS Group upped their price target on shares of IQVIA from $295.00 to $300.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. Four research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $266.67.
View Our Latest Analysis on IQVIA
IQVIA Company Profile
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Stories
- Five stocks we like better than IQVIA
- How to Buy Cheap Stocks Step by Step
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- Buy P&G Now, Before It Sets A New All-Time High
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- Dividend Payout Ratio Calculator
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.